Form 4: Esperion Therapeutics Director Alan Fuhrman Acquires Shares and Options

Director Alan Fuhrman acquired 23,000 shares of Esperion Therapeutics common stock and options to purchase 32,500 shares on May 23, 2024.

Summary

• On May 23, 2024, Alan Fuhrman, a director of Esperion Therapeutics, acquired 23,000 shares of common stock.
• These shares were acquired at a price of $0.
• Following the transaction, Fuhrman directly owns 53,404 shares of Esperion Therapeutics.
• Fuhrman also acquired options to purchase 32,500 shares of common stock with an exercise price of $2.25.
• These options vest fully on the earlier of May 23, 2025, or the Issuer's next annual meeting of stockholders following May 23, 2024, and expire on May 23, 2034.
• Following the transaction, Fuhrman directly owns 32,500 options.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive due to the director's acquisition of shares and options, indicating confidence in the company. However, it's a single transaction and doesn't provide a comprehensive view of the company's overall health.

Positives

• A director's acquisition of shares and options can be seen as a positive signal, indicating confidence in the company's future prospects.

Future Outlook

The document does not contain specific forward-looking statements about the company's future performance, but the director's acquisition of shares and options could be interpreted as a positive sign.

Industry Context

Insider transactions are closely watched by investors as they can provide insights into management's perspective on the company's valuation and future prospects. Director Fuhrman's acquisition could be seen as a bullish signal for Esperion Therapeutics.

Stakeholder Impact

• The director's purchase may positively influence shareholder sentiment.

Key Dates